The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hernández, J.
Right arrow Articles by Sherman, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hernández, J.
Right arrow Articles by Sherman, L. A.
The Journal of Immunology, 2000, 164: 596-602.
Copyright © 2000 by The American Association of Immunologists

The Use of HLA A2.1/p53 Peptide Tetramers to Visualize the Impact of Self Tolerance on the TCR Repertoire1

Javier Hernández*, Peter P. Lee{dagger}, Mark M. Davis{dagger},{ddagger} and Linda A. Sherman2,*

* Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037; and {dagger} Department of Microbiology and Immunology, and {ddagger} Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
p53 is an attractive target for cancer immunotherapy since it is overexpressed in half of all tumors. However, it is also expressed in normal lymphoid tissue, and self tolerance leaves a p53-specific repertoire purged of high avidity CTL. To better understand the mechanism of tolerance and the basis for such low avidity interaction, p53-specific CTL from p53 deficient (p53-) and sufficient (p53+) A2.1/Kb transgenic mice were compared with respect to their ability to bind HLA-A2.1 tetramers containing cognate murine p53 peptide Ag, p53 261–269. Since the murine CD8 molecule cannot interact with human HLA-A2.1, this tests the ability of the TCR to bind the A2.1/peptide complex tetramer. CTL from p53- mice demonstrated strong binding of such A2.1/p53 261–269 tetramers; however, the CTL from tolerant p53+ mice were devoid of tetramer-binding CD8+ T cells. Examination of TCR expression at the clonal level revealed that CTL from p53+ and p53- mice each expressed comparable levels of the p53-specific TCR. These results indicate that normal expression of p53 promotes elimination of T cells expressing TCRs with sufficient affinity to achieve stable binding of the A2.1/p53 261–269 tetramers.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
To avoid autoimmunity, the immune system has developed multiple strategies by which T cells can achieve tolerance to self Ags. The issue of self tolerance has increasingly become of concern in tumor immunology, since many promising candidates for tumor Ags are derived from proteins that are also expressed on normal tissue (1, 2, 3, 4, 5). However, not much information is available concerning the extent to which self tolerance has shaped the repertoire specific for these tumor Ags.

The first and arguably most effective form of self tolerance is thymic deletion, by which thymocytes recognizing self peptides undergo apoptosis (6, 7, 8). This process, however, is highly dependent on the avidity of T cell recognition and the amount of epitope presented in the thymus (9, 10, 11, 12). As a consequence, many T cells that recognize self epitopes with an avidity below a certain threshold are permitted access to the periphery (13, 14, 15). In addition to thymic tolerance, antigenic encounter in the periphery, in the absence of the appropriate immunostimulatory environment, can lead to deletion or anergy (16, 17, 18, 19, 20, 21). However, the presence of the Ag in the periphery does not always affect T cells, and some may remain ignorant of Ag (22). Again, this is likely to be determined by T cell avidity and the amount of Ag presented in the periphery.

We and others have been studying the feasibility of targeting p53 as a tumor Ag since it is overexposed in more than half of all human tumors (23). However, p53 is expressed in normal tissues, including thymus, spleen, and lymphohemopoietic cells (24, 25, 26), and may act as a tolerogen during thymic development and in the periphery (5, 27). Previously, we compared the HLA-A2.1-restricted response to p53 epitopes in p53 deficient (p53-) and sufficient (p53+) HLA-A2.1/Kb transgenic mice (27). The effect of tolerance varied for different peptides. CTL specific for the epitope spanning residues 187–197 were completely eliminated in p53+ A2.1/Kb mice (27). In contrast, a CTL response specific for the 261–269 epitope was detected in p53+ mice; however, it was of low avidity as compared with CTL from p53- mice and required more than 10-fold more peptide to achieve the same levels of lysis (27). This low avidity repertoire is likely to represent the only CTL precursors available for activation by a putative vaccine or immunotherapeutic agent targeting p53 and, as such, merits further examination.

In this report we have used A2.1/peptide tetramers for further characterization of the residual low avidity A2.1/Kb-restricted p53 261–269-specific CTL by comparing the ability of CTL from p53+ and p53- A2.1/Kb mice to bind A2.1/p53 261–269 tetramers (28, 29). The results demonstrate that this self tumor Ag promotes functional deletion of the CD8+ T cells carrying TCRs with the highest affinity for p53, resulting in CTL incapable of stable binding to the tetramer complexes.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

All mice used in these studies are on a C57BL/6 background. p53+ A2.1/Kb and p53- A2.1/Kb transgenic mice have already been described (27, 30). p53- mice were obtained from Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA) and mated with A2.1/Kb transgenics. Progeny were interbred, and offspring were screened for mice that were p53-/- and expressed A2.1/Kb. C57BL/6 mice were purchased from the breading colony of The Scripps Research Institute. Mice were propagated and maintained under specific pathogen-free conditions in our vivarium at The Scripps Research Institute. All experimental procedures were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Cell lines

The T2 cell line, which is deficient in TAP, was propagated in RPMI 1640 media containing 10% FBS, 2 mM glutamine, 5 x 10-5 M 2-ME and 50 µg/ml gentamicin sulfate (complete media). EL4-A2.1/Kb and Jurkat-A2.1 transfectants have already been described (27, 30). They were propagated in complete media supplemented with 0.4 mg/ml G418 (Gemini Bio-Products, Calabasas, CA).

Derivation of p53+ A2.1/Kb and p53- A2.1/Kb effector CTL lines

The procedure used to obtain peptide-specific CTL lines has been described (27). Briefly, mice were injected s.c. at the base of the tail with 100 µg of either murine p53 261–269 peptide or human p53 149–157 peptide along with 120 µg of the I-Ab T helper peptide 128–140 of the hepatitis B virus core protein in IFA. After 10 days, mice were sacrificed, and spleen cells were stimulated in vitro (using 24-well plates) with irradiated LPS-activated syngeneic spleen cells pulsed with the priming peptide at 5 µg/ml in complete media. On day 6, effector cells were assayed for their lytic activity. The resultant effector CTL lines were restimulated weekly with irradiated EL4-A2.1/Kb cells (0.5 x 106 cells/well) pulsed with peptide and C57BL/6 spleen cells (6 x 106 cells/well) as fillers in complete media supplemented with 2% supernatant from Con A-stimulated rat spleen cells (27). On day 4 after restimulation, cells were tested in a standard 4-h 51Cr release assay using T2 cells pulsed with different amounts of peptide as targets at the indicated E:T ratio.

CTL clones

p53+ A2.1/Kb 261 clone 12 and 13 were derived from p53+ A2.1/Kb 261 CTL line 3 by limiting dilution methods previously described (31). p53- A2.1/Kb 261 clone 6 and 7 were derived by limiting dilution from the p53- A2.1/Kb CTL line 2, previously sorted in sterile conditions into a CD8+ tetramer+ subpopulation. They were propagated as the parental CTL lines, with 5% instead of 2% rat Con A supernatant. A2.1 149 clone 5 and A2.1 261 clone 45 were derived by limiting dilution from human p53 149–157 and murine p53 261–269, respectively, specific A2.1 CTL lines described previously (27). They were propagated as mentioned above using peptide-pulsed Jurkat-A2.1 cells as APCs instead of EL4-A2.1/Kb.

Tetramer construction and specificity

Production of MHC/peptide tetramers was described in detail elsewhere (28). Briefly, a 15-amino acid substrate peptide for BirA-dependent biotinylation (BSP)3 has been engineered onto the COOH terminus of HLA-A2.1. The A2.1-BSP fusion protein and human {beta}2-microglobulin were expressed in Escherichia coli and were folded in vitro with the specific peptide ligand. The properly folded MHC-peptide complexes were extensively purified using fast performance liquid chromatography and anion exchange, and biotinylated on a single lysine within the BSP using the BirA enzyme (Avidity, Denver, CO). Tetramers were produced by mixing the biotinylated MHC-peptide complexes with PE-conjugated avidin (PharMingen, San Diego, CA) at a molar ratio of 4:1.

HLA A2.1/peptide tetramers used in this study contained either murine p53 261–269 (A2.1/p53 261–269 tetramers), or human p53 149–157 (A2.1/p53 149–157 tetramers). To test their specificity of binding, CTL clones specific for each of these A2.1 binding peptides (27) were stained with both A2.1/p53 261–269 tetramers-PE and A2.1/p53 149–157 tetramers-PE. A2.1 261 clone 45 demonstrated binding of A2.1 tetramers containing its nominal Ag, the murine 261–269 peptide, but not A2.1 tetramers containing the human p53 149–157. Reciprocally, the A2.1 149 clone 5 can be stained specifically by A2.1/p53 149–157 tetramers, but not by A2.1/261–269 tetramers.

Flow cytometry

On day 5 after stimulation, cells were partially purified through a Ficoll-Paque (Pharmacia Biotechnology, Uppsala, Sweden) cushion and then washed in HBSS. Cells (0.5 x 106) were incubated with different combinations of the following staining reagents for 30 min at room temperature in HBSS containing 0.1% BSA and 0.05% sodium azide: A2.1 tetramers-PE described above at 40 µg/ml; anti-murine CD8{alpha}-FITC mAb 53-6.7, at 2 µg/ml; anti-murine pan-TCR{beta}-PE mAb H57-597, at 2 µg/ml; anti-murine CD11a-biotin mAb 2D7, at 1 µg/ml; and streptavidin-FITC, at 5 µg/ml. All reagents were supplied by PharMingen. Propidium iodide was added after the final wash at 1 µg/ml to exclude dead cells in all experiments. Samples were analyzed on a Becton Dickinson (San Jose, CA) FACSort apparatus at The Scripps Research Institute FACS facility. Twenty thousand events were collected and analyzed using CellQuest software (Becton Dickinson).

TCR V{alpha} usage and sequencing of V-J-C junctions region

Poly(A)+ RNA from 4 x 106 cells of the 261–269 peptide-specific CTL clones was extracted using MicroFastTrack Kit (Invitrogen, Carlsbad, CA) following the manufacturer’s instructions. cDNA was synthesized using SuperScript II Reverse Transcriptase (Life Technologies, Gaithersburg, MD) and oligo(dT)12–18 primers (Life Technologies). cDNA (1/100) was used as a template for PCR amplification with 1 unit Taq polymerase (Life Technologies) in a Hybaid thermal cycler (Hybaid, Middlesex, UK). Methods and primer sequences for PCR-based screening of the TCR V{alpha} usage have been previously described (32). PCR fragments obtained from CTL clones 7 and 13 were cloned into pCR2.1 vector using TA Cloning Kit (Invitrogen) and following the manufacturer’s instructions. M13 forward and reverse primers were used to determine sequences of three different molecular clones for each PCR fragment by the Nucleic Acids Core Facility at Scripps Research Institute using Applied Biosystems (Foster City, CA) automated sequencers.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Binding of A2.1/p53 261–269 tetramers by CTL lines from p53+ and p53- mice

Previous experiments suggested a lower avidity A2.1-restricted p53 261–269-specific CTL response in A2.1/Kb transgenics that express p53 than in p53- A2.1/Kb mice, since the first needed a 10-fold higher concentration of peptide to achieve similar levels of lysis (27). As defined, avidity is a multifactorial property in T cell recognition, in which TCR and CD8 are main contributors to variability. Although murine CD8 can interact with the chimeric A2.1/Kb molecule that contains the {alpha}3 domain from the Kb molecule, it does not effectively interact with the intact HLA-A2.1 molecule (30). Accordingly, it is possible to evaluate the contribution of TCR affinity to the overall T cell avidity (in the absence of participation of CD8) by examining its interaction with the intact A2.1 molecule, rather than A2.1/Kb. To do so, we used two different approaches: 1) analysis of the lytic activity of targets expressing A2.1; and 2) analysis of the binding to A2.1/peptide tetramers.

We analyzed the lytic activity of 261–269-specific CTL lines from p53- and p53+ A2.1/Kb using T2 cells loaded with peptide as targets (Fig. 1GoA). The results obtained in the absence of CD8 contribution were similar to those obtained previously when the coreceptor was operative. CTL lines from p53- mice required far less peptide than those from p53+ mice to achieve similar levels of lysis. There is approximately a 10-fold difference between lines 2 and 3 in the amount of peptide required to obtain 50% lysis (Fig. 1GoA). The very same 261–269-specific CTL lines were tested for their ability to bind A2.1/p53 261–269 tetramers (Fig. 1GoB). The p53- CTL lines contained a subset of CD8+ cells capable of binding these tetramers, whereas p53+ lines did not (Fig. 1GoB). An average of 21% of the CD8+ T cells from six different high avidity p53- A2.1/Kb CTL lines analyzed could bind tetramers. In contrast, only an average of 1.2% of the CD8+ T cells from six different low avidity CTL lines from p53+ A2.1/Kb mice could bind tetramer. The level of staining observed using allospecific CTL, an average of 1% of the CD8+ T cells (data not shown), suggested this was the background level in our conditions. Also, no evidence for specific binding could be found among freshly isolated splenocytes from p53 261–269-immunized mice.



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 1. Lytic activity and tetramer binding ability of murine p53 261–269 peptide-specific CTL lines. CTL lines obtained from p53 261–269 peptide-primed p53- and p53+ A2.1/Kb transgenics were analyzed after four weekly rounds of in vitro restimulation. Data from two of six independently established lines from p53- A2.1/Kb mice (lines 1 and 2) and p53+ A2.1/Kb mice (lines 3 and 4) is provided. A, Effector CTL were assayed for lytic activity against T2 cells pulsed with different concentrations of p53 261–269 peptide as indicated at an E:T ratio of 2:1 4 days after restimulation. B, The same CTL lines 1, 2, 3 and 4 were stained on day 5 after restimulation with A2.1/p53 261–269 tetramers-PE and anti CD8{alpha}-FITC.

 
Despite their inability to bind A2.1/p53 261–269 tetramers, these CTL specifically lysed A2.1-expressing cells loaded with the 261–269 peptide (Fig. 1GoA). Taken together with the results of the cytolytic assay using A2.1 targets, there is good correlation between high avidity, as defined by the lytic assay, and tetramer binding.

Tetramer binding of cloned CTL from p53- and p53+ mice

The poor binding and lysis exhibited by p53+ A2.1/Kb lines could be explained by the presence in these CTL populations of a very few T cells that are actually specific for this complex and capable of binding and cytolysis. To determine whether cells that did not demonstrate tetramer binding could actually be responsible for specific lysis, CTL clones were derived from p53+ A2.1/Kb CTL line 3 by limiting dilution (Fig. 2GoA). As a control, clones were also isolated from the tetramer binding, CTL line 2 derived from a p53- mouse (Fig. 2GoA). Resulting clones were tested for both tetramer binding (Fig. 2GoB) and lytic activity (Fig. 2GoC). Clones 12 and 13 were unable to bind stably A2.1/p53 261–269 tetramers, whereas clones 6 and 7 demonstrated staining, although at different levels (Fig. 2GoB). Both tetramer+ and tetramer- clones were able to kill specifically p53 261–269 peptide-loaded T2 targets; however, they displayed different lytic capabilities (Fig. 2GoC). A 10-fold difference in avidity in the dose-response curve translated into either strong tetramer binding as exhibited by clone 7 or no binding at all, as observed for clone 13 (Fig. 2Go, B and C). Clones displaying p53 261–269-specific lytic activity yet unable to bind tetramer were also isolated from a CD8+ tetramer- subpopulation from p53- CTL line 2 (data not shown), indicating the presence of both high and low avidity CTL in this population.



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 2. Isolation and characterization of tetramer+ and tetramer- murine p53 261–269 peptide-specific CTL clones. A, Schematic representation of the origin of p53- A2.1/Kb clones 6 and 7 and p53+ A2.1/Kb clones 12 and 13. B, p53 261–269 peptide-specific clones were stained with A2.1/p53 261–269 tetramers-PE on day 5 after restimulation. Shaded profiles correspond to unstained controls. C, The lytic activity of clones 6, 7, 12, and 13 was assessed on day 4 after restimulation using T2 cells pulsed with the indicated concentrations of p53 261–269 peptide as targets at an E:T ratio of 2:1.

 
It has been shown previously that one way to achieve tolerance and a low avidity phenotype is by decreasing the density of the specific TCR on the cell surface (33, 34, 35). We therefore examined the levels of total TCR on the surface of both tetramer+ high avidity and tetramer- low avidity clones, and no significant differences were observed (Fig. 3Go). Surface TCR levels were also equivalent in the CTL lines described above (data not shown). Even when total levels of TCR were similar, the expression of a second {alpha}-chain, which can compete for the same {beta}-chain to produce another TCR with a different specificity, may reduce the actual density of the TCR specific for nominal Ag (36, 37, 38). To test this possibility, a fragment containing the V-J-C junctions region of the TCR {alpha}-chain mRNA from clones 7 and 13 was amplified and sequenced (Fig. 4Go). Two different {alpha}-chain mRNA were found in each clone, but only one was productively rearranged: V{alpha}3-J{alpha}17-C{alpha}, in clone 7; and V{alpha}1-J{alpha}8-C{alpha}, in clone 13 (Fig. 4Go). Analysis of the TCR V{alpha} usage by PCR for clones 6 and 12 revealed identical results to that obtained for clones 7 and 13, respectively (data not shown). This suggested that they could be clonally related.



View larger version (50K):
[in this window]
[in a new window]
  		FIGURE 3. Expression of surface receptors in tetramer+ and tetramer- murine p53 261–269 peptide-specific CTL clones. Analysis of total TCR, CD8, and LFA-1 surface expression of clones described in Fig. 3Go on day 5 after restimulation with an anti-murine pan-TCR{beta}-PE, anti CD8{alpha}-FITC, and biotinylated anti-CD11a plus streptavidin-FITC. Shaded profiles correspond to unstained controls.

 


View larger version (49K):
[in this window]
[in a new window]
  		FIGURE 4. Expression of TCR {alpha}-chain in murine p53 261–269 peptide-specific CTL clones. Expression of two different TCR {alpha}-chain mRNA was found in each of the tetramer+ and tetramer- clones analyzed using the method described by Zisman et al. (32 ). Partial sequences containing the V-J-C junctions region of TCR {alpha}-chains found in clones 7 and 13 are presented. Each clone expressed a productive and a nonproductively rearranged sequence. These sequence data are available from EMBL/GenBank/DDBJ under accession numbers AF151729, AF151730, AF15131, and AF151732.

 
Finally, the expression of CD8 and LFA-1 was analyzed, since interaction with its ligands plays an important role in T cell avidity (30, 39, 40, 41, 42). Again, no significant differences were observed (Fig. 3Go). Taken together, these results suggest a difference in TCR affinity is responsible for the difference in lytic ability and tetramer binding observed between CTL from p53+ and p53- mice. Thus, A2.1 tetramers can discriminate the distribution of affinities present in a CTL population. Only the highest affinity TCRs can be detected by FACS. It is also likely that the difference in intensity of tetramer staining between clones 6 and 7 (mean fluorescence intensity of 52 for clone 6, and 202 for clone 7) reflects differences in their TCR affinities (Fig. 2Go). However, since cell surface TCR expression of clone 6 is 50% lower than that of clone 7 (Fig. 3Go), the lower level of tetramer binding may also reflect a difference in TCR density.

p53+ A2.1/Kb CTL are not tolerant of human p53 149–157 foreign peptide

To ascertain that the differences between the CTL obtained from p53 expressing and p53 deficient mice were actually related to the fact the epitope under examination induced tolerance in the p53-expressing mice, we examined the CTL responses by these same mice against a peptide epitope that is not expressed in either strain of mouse. The human p53 149–157 epitope is also A2.1 restricted, yet its sequence differs from the murine molecule by 3 amino acids (27, 43). The avidity of the CTL response is almost identical in both p53- A2.1/Kb and p53+ A2.1/Kb mice, showing that A2.1/Kb mice are not tolerant of this peptide (27). 149–157-specific CTL lines from both types of mice were obtained. Their lytic activity on T2 targets and their ability to bind specific A2.1/p53 149–157 tetramers were analyzed (Fig. 5Go). When using T2 targets, the avidity of p53- A2.1/Kb and p53+ A2.1/Kb CTL was identical (Fig. 5GoA), and the tetramer staining patterns were highly comparable (Fig. 5GoB). All CTL lines tested from both p53- A2.1/Kb and p53+ A2.1/Kb mice contained CD8+ T cells capable of binding A2.1/p53 149–157 tetramers.



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 5. Lytic activity and tetramer binding ability of human p53 149–157 peptide-specific CTL lines. CTL lines from human p53 149–157 peptide-primed p53- and p53+ A2.1/Kb transgenics were analyzed after four weekly rounds of in vitro restimulation. One representative p53- A2.1/Kb line and one representative p53+ A2.1/Kb line are shown. A, Four days after restimulation, effector CTL were assayed for lytic activity against T2 cells pulsed with different concentrations of p53 149–157 peptide as indicated at an E:T ratio of 2:1. B, The same CTL lines were stained on day 5 after restimulation with A2.1/p53 149–157 tetramers-PE and anti- CD8{alpha}-FITC.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Understanding the mechanisms of tolerance and its consequences to the T cell repertoire specific for self epitopes is of particular importance in autoimmunity and tumor immunity. Many potential tumor Ags are known to be expressed in normal as well as transformed cells (1, 2, 3, 4, 5). Our studies with p53 have indicated that tolerance is achieved by functionally eliminating T cells with high avidity (27). It is these residual low avidity CTL that constitute the repertoire available to a potential vaccine or immunotherapeutic agent. The goal of this study was to evaluate the contribution of each of several different variables, known to alter T cell avidity, in effecting tolerance to p53. Included among these was density of TCR specific for the tolerogen, and alterations in nonclonotypic molecules that alter T cell avidity, such as the CD8 coreceptor and the LFA-1 adhesion molecule (30, 33, 39, 40, 42). Although no evidence was obtained for alteration in expression of nonclonotypic molecules, by using A2.1/p53 261–269 tetramers, it was immediately apparent that there was a significant difference in CTL from p53+ and p53- mice in their TCR binding of this self Ag.

Whereas p53 261–269-specific CTL obtained from p53- mice demonstrated a population of CD8+ T cells capable of binding A2.1/p53 261–269 tetramers, CTL of similar specificity obtained from p53+ mice did not demonstrate stable binding of these tetramers. The small numbers of CD8+ tetramer+ cells that were detected in p53+ A2.1/Kb CTL lines (1%) most likely represent background staining, since similar numbers of tetramer-stained cells were found in alloreactive CTL. Also, whereas p53- A2.1/Kb CTL lines maintained in vitro for prolonged periods of time demonstrated an enrichment of the tetramer-binding subpopulation, no such increase in the numbers of tetramer-binding CD8+ T cells was observed in the CTL populations from p53+ mice (data not shown). One possible explanation for the lack of high avidity (tetramer+) CD8+ T cells in the 261-specific CTL lines from p53+ mice is related to the relatively high concentration of peptide used for their propagation in vitro. It has been shown that high concentrations of peptide may induce apoptosis of high avidity CTL (44). However, since identical concentrations of peptide were used to propagate 261-specific CTL from p53- mice, which were capable of strong tetramer binding, it is unlikely this can explain the lack of tetramer binding among 261-specific CTL from p53+ mice. Also, 149-specific CTL from both p53+ and p53- mice stimulated under the same conditions contained high avidity CD8+ T cells capable of tetramer binding.

Our studies found no evidence for down-regulation of TCR levels or expression of a second TCR as a mechanism for decreasing T cell avidity in p53+ mice. The later was somewhat surprising since it is well documented that more than one TCR can normally be expressed by T cells, thereby decreasing the actual concentration of the TCR specific for the first epitope (36, 37, 38, 45, 46). It has been shown in TCR transgenic models how down-regulation of the total levels of TCR may allow T cells to escape tolerance (33). Also, it was shown using TCR transgenics that cells expressing an autoreactive TCR can escape thymic deletion if they express a second TCR (34, 35). Perhaps more extensive analysis of T cell clones from p53-expressing mice will reveal CD8+ cells that have escaped tolerance by expression of a second TCR. Alternatively, it is possible that, for this particular Ag, it was not possible to achieve sufficiently low avidity to avoid deletion by these alternative mechanism.

p53 261–269-specific effector CTL from p53- mice and p53 149–157-specific CTL from either p53- or p53+ mice contain a mixture of both specific tetramer binding and nonbinding CD8+ T cells. These results indicate that, in response to a foreign peptide Ag, a heterogeneous set of TCR affinities may arise, including CTL with a relative high affinity TCR, as well as very low avidity CTL. Furthermore, the use of MHC tetramers represents an important tool to separate CTL by avidity. Several reports have correlated differences in the intensity of tetramer staining with differences in TCR affinity for the Ag for both class II and class I MHC tetramers (47, 48, 49, 50). Interestingly, in two of these reports it has been demonstrated that a higher intensity of tetramer staining reflects a lower tetramer dissociation rate (49, 50). Probably, the dissociation rate of the A2.1/p53 peptide tetramers is too high to detect binding to the low affinity p53-specific TCR by FACS. However, the difference in avidity, as measured in a cytolysis assay, between the CTL that bind tetramer and those that cannot is quite narrow, no higher than 10-fold.

The existence of CD8+ T cells within p53 261–269 peptide-specific CTL lines, which are not able to bind tetramers yet display specific lytic activity, contrasts with results from several other studies using HLA A2.1, Mamu-A0.1, or Kb tetramers. It was reported that the tetramer+ but not tetramer- cells from human, monkey, or mouse effector CTL were able to lyse peptide-pulsed targets (28, 51, 52, 53). An explanation for these different findings is that human CD8+ T cells bind A2.1 tetramers better than murine CTL do. In previous studies, some contribution to the avidity of tetramer binding may have come from CD8 (M. M. Davis, unpublished observation). In the current study, since murine CD8 does not bind the human A2.1 molecule, this interaction was not possible and therefore could not increase the avidity of tetramer binding to the CTL. This suggests that, in the absence of CD8 contribution, cytotoxicity assays are more sensitive than tetramer binding in detecting murine A2.1-restricted 261–269-specific CTL.

The experiments presented here suggest the occurrence of functional elimination of the CD8+ T cells carrying TCRs with relatively high affinity for the Ag, when it is expressed as a normal self Ag. Since there is expression of p53 in the thymus (24, 25, 26), it is likely that high avidity interaction with physiological amounts of the 261–269 peptide on thymic APCs results in negative selection. On the other hand, thymocytes expressing TCRs that have low affinity for this peptide may be positively selected in the same environment. Using TCR transgenic mice, several studies have demonstrated that weak agonist peptides are capable of positive selection (10, 54, 55, 56, 57). It is interesting to speculate that the 261–269 endogenous peptide may have contributed to the selection of some of the peptide-specific CTL obtained from p53+ mice.

In summary, this study shows the mechanism by which functional tolerance to a natural self epitope has been achieved. TCR affinity for a given MHC class I/peptide complex appears to be the main factor determining the overall avidity in CTL recognition for p53. In order for a potentially autoreactive T cell to be maintained in the repertoire, its TCR affinity must be kept under a certain threshold. The existence of a residual p53-specific, low avidity effector CTL could provide a window of opportunity for tumor rejection. Promisingly, two recent studies have demonstrated it is possible to activate CTL specific for self epitopes, such as p53, and get tumor rejection by the use of viral vectors or dendritic cells as vaccines (58, 59). Future studies will compare the ability of CTL-expressing high and low affinity TCRs to eliminate tumors in vivo.


   Acknowledgments
 
We thank Judy Biggs, Karen Holst, and Alice Ko for excellent technical assistance, and Carol Wood for secretarial assistance.


   Footnotes
 
1 This work was supported by National Institutes of Health Grants CA 25803 and CA 57885 (to L.A.S.) and by Howard Hughes Medical Institute (M.M.D.). Back

2 Address correspondence and reprint requests to Dr. Linda A. Sherman, Department of Immunology, Scripps Research Institute, 10550 North Torrey Pines Road, IMM-15, La Jolla, CA 92037. E-mail address: Back

3 Abbreviation used in this paper: BSP, BirA-dependent biotinylation substrate peptide. Back

Received for publication August 13, 1999. Accepted for publication October 26, 1999.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Houghton, A. N.. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1.[Free Full Text]
  2. Nanda, N. K., E. E. Sercarz. 1995. Induction of anti-self-immunity to cure cancer. Cell 82:13.[Medline]
  3. Boon, T., P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.[Free Full Text]
  4. van den Eynde, B. J., P. van der Bruggen. 1997. T cell defined tumor antigens. Curr. Opin. Immunol. 9:684.[Medline]
  5. Sherman, L. A., M. Theobald, D. Morgan, J. Hernandez, I. Bacick, J. Yewdell, J. Bennink, J. Biggs. 1998. Strategies for tumor elimination by cytotoxic T lymphocytes. Crit. Rev. Immunol. 18:47.[Medline]
  6. Kappler, J. W., N. Roehm, P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273.[Medline]
  7. Kisielow, P., H. Bluthmann, U. D. Staerz, M. Steinmetz, H. von Boehmer. 1988. Tolerance in T cell receptor transgenic mice involves deletion of non mature CD4+8- thymocytes. Nature 333:742.[Medline]
  8. Surh, C. D., and J. Sprent. 1994. T cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372.
  9. Cibotti, R., J. M. Kanellopoulos, J.-P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, E. Sercarz, P. Kourilsky. 1992. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 89:416.[Abstract/Free Full Text]
  10. Ashton-Rickardt, P. G., A. Bandeira, J. R. Delaney, L. V. Kaer, H.-P. Pircher, R. M. Zinkernagel, S. Tonegawa. 1994. Evidence for a differential avidity model of T cell selection in the thymus. Cell 76:651.[Medline]
  11. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.[Medline]
  12. Sebzda, E., V. A. Wallace, J. Mayer, R. S. Yeung, T. W. Mak, P. S. Ohashi. 1994. Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science 263:1615.[Abstract/Free Full Text]
  13. Oehen, S. U., P. S. Ohashi, K. Burki, H. Hengartner, R. M. Zinkernagel, P. Aichele. 1994. Escape of thymocytes and mature T cells from clonal deletion due to limiting tolerogen expression levels. Cell. Immunol. 158:342.[Medline]
  14. Liu, G. Y., P. J. Fairchild, R. M. Smith, J. R. Prowle, D. Kioussis, D. C. Wraith. 1995. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3:407.[Medline]
  15. Kawai, K., P. S. Ohashi. 1995. Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature 374:68.[Medline]
  16. Webb, S., C. Morris, J. Sprent. 1990. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63:1249.[Medline]
  17. Kawabe, Y., A. Ochi. 1991. Programmed cell death and extra thymic reduction of V{beta}8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature 349:245.[Medline]
  18. Rocha, B., H. von Boehmer. 1991. Peripheral selection of the T cell repertoire. Science 251:1225.[Abstract/Free Full Text]
  19. Moskophidis, D., F. Lechner, H. Pircher, R. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:728.
  20. Schwartz, R. H.. 1996. Models of T cell anergy: is there a common molecular mechanism. J. Exp. Med. 184:1.[Free Full Text]
  21. Gütgemann, I., A. M. Fahrer, J. D. Altman, M. M. Davis, Y. Chien. 1998. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen. Immunity 8:667.[Medline]
  22. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkernagel, H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305.[Medline]
  23. Levine, A. J., J. Momand, C. A. Finlay. 1991. The p53 tumor suppressor gene. Nature 351:453.[Medline]
  24. Milner, J.. 1984. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 310:143.[Medline]
  25. Rogel, A., M. Popliker, C. G. Webb, M. Oren. 1985. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol. 5:2851.[Abstract/Free Full Text]
  26. Terada, N., J. J. Lucas, E. W. Gelfand. 1991. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb), and p53 during cell cycle progression of normal human T cells. J. Immunol. 147:698.[Abstract]
  27. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185:833.[Abstract/Free Full Text]
  28. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.[Abstract/Free Full Text]
  29. McMichael, A. J., C. A. O’Callaghan. 1998. A new look at T cells. J. Exp. Med. 187:1367.[Free Full Text]
  30. Sherman, L. A., S. V. Hesse, M. J. Irwin, D. L. Face, P. Peterson. 1992. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 258:815.[Abstract/Free Full Text]
  31. Vitiello, A., L. A. Sherman. 1983. Recognition of influenza-infected cells by cytolytic T lymphocyte clones: determinant selection by class I restriction elements. J. Immunol. 131:1635.[Abstract]
  32. Zisman, E., M. Sela, A. Ben-Nun, E. Mozes. 1994. Dichotomy between the T and the B cell epitopes of the synthetic polypeptide (T,G)-A—L*. Eur. J. Immunol. 24:2497.[Medline]
  33. Schönrich, G., U. Kalinke, F. Momburg, M. Malissen, A. M. Scmitt-Verhulst, B. Malissen, G. J. Hammerling, B. Arnold. 1991. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extra-thymic tolerance induction. Cell 65:293.[Medline]
  34. Sarukhan, A., C. Garcia, A. Lanoue, H. von Boehmer. 1998. Allelic inclusion of T cell receptor a genes poses an autoimmune hazard due to low-level expression of autospecific receptors. Immunity 8:563.[Medline]
  35. Girgis, L., M. M. Davis, B. Fazekas de St. Groth.. 1999. The avidity spectrum of T cell receptor interactions accounts for T cell anergy in a double transgenic model. J. Exp. Med. 189:265.[Abstract/Free Full Text]
  36. Casanova, J. L., P. Romero, C. Widmann, P. Kourilsky, J. L. Maryansky. 1991. T cell receptor genes in a series of class I major histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a Plasmodium berghei nonapeptide: implications for T cell allelic exclusion and antigen-specific repertoire. J. Exp. Med. 174:1371.[Abstract/Free Full Text]
  37. Heath, W. R., J. F. Miller. 1993. Expression of two {alpha} chains on the surface of T cells in T cell receptor transgenic mice. J. Exp. Med. 178:1807.[Abstract/Free Full Text]
  38. Heath, W. R., F. R. Carbone, P. Bertolino, J. Kelly, S. Cose, J. F. A. P. Miller. 1995. Expression of two T cell receptor {alpha} chains on the surface of normal murine T cells. Eur. J. Immunol. 25:1617.[Medline]
  39. Lee, N. A., D. Y. Loh, E. Lacy. 1992. CD8 Surface levels alter the fate of {alpha}/{beta} T cell receptor-expressing thymocytes in transgenic mice. J. Exp. Med. 175:1013.[Abstract/Free Full Text]
  40. Robey, E. A., F. Ramsdell, D. Kioussis, W. Sha, D. Loh, R. Axel, B. J. Fowlkes. 1992. The level of CD8 expression can determine the outcome of thymic selection. Cell 69:1089.[Medline]
  41. Bachmann, M. F., E. Sebzda, T. M. Kundig, A. Shahinian, D. E. Speiser, T. W. Mak, P. S. Ohashi. 1996. T cell responses are governed by avidity and costimulatory thresholds. Eur. J. Immunol. 26:2017.[Medline]
  42. Bachmann, M. F., K. Mckall-Faienza, R. Schmits, D. Bouchard, J. Beach, D. E. Speiser, T. W. Mak, P. S. Ohashi. 1997. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7:549.[Medline]
  43. Theobald, M., J. Biggs, D. Dittmer, A. J. Levine, L. A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92:11993.[Abstract/Free Full Text]
  44. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, J. A. Berzofsky. 1996. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485.[Abstract/Free Full Text]
  45. Marolleau, J. P., J. D. Fondel, M. Malissen, J. Trucy, E. Barbier, K. B. Marcu, P. A. Cazenave, D. Primi. 1988. The joining of germ-line V{alpha} to J{alpha} genes replaces the preexisting V{alpha}-J{alpha} complexes in a T cell receptor {alpha},{beta} positive T cell line. Cell 55:291.[Medline]
  46. Padovan, E., G. Casorali, P. Dellatona, S. Meyer, M. Brockhaus, A. Lanzavecchia. 1993. Expression of two T cell receptor {alpha} chains: dual receptor T cells. Science 262:422.[Abstract/Free Full Text]
  47. Crawford, F., H. Kozono, J. White, P. Marrack, J. Kappler. 1998. Detection of antigen-specific T cells with multivalent soluble Class II MHC covalent peptide complexes. Immunity 8:675.[Medline]
  48. Yee, C., P. A. Savage, P. P. Lee, M. M. Davis, P. D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162:2227.[Abstract/Free Full Text]
  49. Busch, D. H., E. G. Pamer. 1999. T cell affinity maturation by selective expansion during infection. J. Exp. Med. 189:701.[Abstract/Free Full Text]
  50. Savage, P. A., J. J. Boniface, M. M. Davis. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10:485.[Medline]
  51. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. Chen, D. Lienard, J.-C. Cerottini, V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.[Abstract/Free Full Text]
  52. Kuroda, M. J., J. E. Schmitz, D. H. Barouch, A. Craiu, T. M. Allen, A. Sette, D. I. Watkins, M. A. Forman, N. L. Letvin. 1998. Analysis of Gag-specific cytotoxic T lymphocytes in Simian immunodeficiency virus-infected Rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J. Exp. Med. 187:1373.[Abstract/Free Full Text]
  53. Bousso, P., A. Casrouge, J. D. Altman, M. Haury, J. Kanellopoulos, J. P. Abastado, P. Kourilsky. 1998. Individual variations in the murine T cell response to a specific peptide reflect variability in naive repertoires. Immunity 9:169.[Medline]
  54. Hogquist, K. A., S. C. Jameson, M. C. Bevan. 1995. Strong agonist ligands for the T cell receptor do not mediate positive selection of functional CD8+ T cells. Immunity 3:79.[Medline]
  55. Sebzda, E., T. M. Kündig, C. T. Thomson, K. Aoki, S.-Y. Mak, J. P. Mayer, T. Zamborelli, S. G. Nathenson, P. S. Ohasi. 1996. Mature T cell reactivity altered by peptide agonist that induces positive selection. J. Exp. Med. 183:1093.[Abstract/Free Full Text]
  56. Pawlowski, T. J., M. D. Singleton, D. Y. Loh, R. Berg, U. D. Staerz. 1996. Permissive recognition during positive selection. Eur. J. Immunol. 26:851.[Medline]
  57. Girao, C., Q. Hu, J. Sun, P. G. Ashton-Rickardt. 1997. Limits to the differential avidity model of T cell selection in the thymus. J. Immunol. 159:4205.[Abstract]
  58. Morgan, D. J., H. T. C. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643.[Abstract/Free Full Text]
  59. Gong, J., D. Chen, M. Kashiwaba, Y. Li, L. Chen, H. Takeuchi, H. Qu, G. J. Rowse, S. J. Genler, D. Kufe. 1998. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95:6279.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
R. Sartorius, P. Pisu, L. D'Apice, L. Pizzella, C. Romano, G. Cortese, A. Giorgini, A. Santoni, F. Velotti, and P. De Berardinis
The Use of Filamentous Bacteriophage fd to Deliver MAGE-A10 or MAGE-A3 HLA-A2-Restricted Peptides and to Induce Strong Antitumor CTL Responses
J. Immunol., March 15, 2008; 180(6): 3719 - 3728.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. M. Lauwen, S. Zwaveling, L. de Quartel, S. C. Ferreira Mota, J. A.C. Grashorn, C. J.M. Melief, S. H. van der Burg, and R. Offringa
Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen
Cancer Res., February 1, 2008; 68(3): 893 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. N. Kochenderfer and R. E. Gress
A Comparison and Critical Analysis of Preclinical Anticancer Vaccination Strategies
Experimental Biology and Medicine, October 1, 2007; 232(9): 1130 - 1141.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Laugel, H. A. van den Berg, E. Gostick, D. K. Cole, L. Wooldridge, J. Boulter, A. Milicic, D. A. Price, and A. K. Sewell
Different T Cell Receptor Affinity Thresholds and CD8 Coreceptor Dependence Govern Cytotoxic T Lymphocyte Activation and Tetramer Binding Properties
J. Biol. Chem., August 17, 2007; 282(33): 23799 - 23810.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. A. Johnson, B. Heemskerk, D. J. Powell Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg
Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes
J. Immunol., November 1, 2006; 177(9): 6548 - 6559.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. de Witte, M. Coccoris, M. C. Wolkers, M. D. van den Boom, E. M. Mesman, J.-Y. Song, M. van der Valk, J. B. A. G. Haanen, and T. N. M. Schumacher
Targeting self-antigens through allogeneic TCR gene transfer
Blood, August 1, 2006; 108(3): 870 - 877.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Benigni, V. S. Zimmermann, S. Hugues, S. Caserta, V. Basso, L. Rivino, E. Ingulli, L. Malherbe, N. Glaichenhaus, and A. Mondino
Phenotype and Homing of CD4 Tumor-Specific T Cells Is Modulated by Tumor Bulk
J. Immunol., July 15, 2005; 175(2): 739 - 748.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A. M. Ercolini, B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J.-P. H. Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
J. Exp. Med., May 16, 2005; 201(10): 1591 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Kawano, C. L. Efferson, G. E. Peoples, D. Carter, N. Tsuda, J. L. Murray, and C. G. Ioannides
Sensitivity of Undifferentiated, High-TCR Density CD8+ Cells to Methylene Groups Appended to Tumor Antigen Determines Their Differentiation or Death
Cancer Res., April 1, 2005; 65(7): 2930 - 2937.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. A. Lyman, C. T. Nugent, K. L. Marquardt, J. A. Biggs, E. G. Pamer, and L. A. Sherman
The Fate of Low Affinity Tumor-Specific CD8+ T Cells in Tumor-Bearing Mice
J. Immunol., March 1, 2005; 174(5): 2563 - 2572.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Daftarian, G.-Y. Song, S. Ali, M. Faynsod, J. Longmate, D. J. Diamond, and J. D. I. Ellenhorn
Two Distinct Pathways of Immuno-Modulation Improve Potency of p53 Immunization in Rejecting Established Tumors
Cancer Res., August 1, 2004; 64(15): 5407 - 5414.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Wang, H. Chen, X. Jiang, M. Zhang, T. Wan, N. Li, X. Zhou, Y. Wu, F. Yang, Y. Yu, et al.
Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein
Blood, July 1, 2004; 104(1): 200 - 206.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. M.-L. Choi, J.-L. Chen, L. Wooldridge, M. Salio, A. Lissina, N. Lissin, I. F. Hermans, J. D. Silk, F. Mirza, M. J. Palmowski, et al.
High Avidity Antigen-Specific CTL Identified by CD8-Independent Tetramer Staining
J. Immunol., November 15, 2003; 171(10): 5116 - 5123.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Espenschied, J. Lamont, J. Longmate, S. Pendas, Z. Wang, D. J. Diamond, and J. D. I. Ellenhorn
CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model
J. Immunol., March 15, 2003; 170(6): 3401 - 3407.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. La Rosa, Z. Wang, J. C. Brewer, S. F. Lacey, M. C. Villacres, R. Sharan, R. Krishnan, M. Crooks, S. Markel, R. Maas, et al.
Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice
Blood, November 15, 2002; 100(10): 3681 - 3689.
[Abstract] [Full Text] [PDF]

Home page